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Reviewer 1 
Excellent manuscript. I have only some minor points. 
Thank you for sharing this judgement.  
 
1) Please use "migraine patient" instead of "migraineur" 
The word migraineur is correct (OED); there is no pressing, globally accepted view to insert two words 
when there is one English word that can be used. 
 
2) page 11, line 44: "Experiments were conducted all studies were conducted..." Please correct 
Thanks for picking up this mistake. It has now been corrected.  
 
3) Could you please state in which years and in which laboratory exactly the experiments were 
conducted 
The generation of the antibody Ab181, in vitro characterization of Ab181, pharmacokinetic and 
pharmacodynamic analyses as well as the immunohistochemistry were all conducted between 2011 and 
2013 in the Amgen laboratories in Thousand Oaks, CA, USA. The electrophysiology experiments were all 
conducted between 2012 and 2013 at the University of California San Francisco, CA, USA. We have now 
stated this in the manuscript.  
  
4) page 24: I think it is too early to conclude that there is only a peripheral mode of action. Given the 
differences between the animal model and humans reagrding blood brain barrier etc., it might be that 
in humans there is a central site of action. Also, it is not yet proven that high concentrations of Ab181 
are needed for the main mechanism. It could also be that the main mechanism is located in the CNS 
and that small amounts of Ab181 are sufficient. 





The authors describe the development of a rodent-specific PAC1 receptor antibody (Ab181) and its 
effect on nociceptive neuronal activity in the trigemino-cervical complex. By doing so, they show that 
AB181 inhibits stimulus-evoked activity in the trigemino-cervical complex but not spontaneous 
neuronal activity. Using immunohistochemistry, they demonstrate that the antibody binds in the 
trigeminal ganglion and SPG but not within the CNS. The authors conclude that a PAC1 receptor 
antibody could provide potential benefit in treatment of primary headache. This manuscript adds 
important findings to the field because the potential benefit of PACAP antagonism in primary 
headache prevention is an ongoing discussion. However, I have few points to be addressed: 
 
Results: 
Dose response studies at 48h and 3.25 h. How did the authors choose these time points? 
The time points were chosen to confirm that the receptor occupancy of Ab181 has reached and stayed 
at the desired pharmacodynamic measures during the entire duration of the electrophysiology 
experiments. We have now specified this in the manuscript. 
 
Effect of Ab181 on neuronal activity in TCC: N number is missing. How many in vivo experiments in 
how many rats were performed? This is important for the interpretation of the main findings. 
In the methods section under the subheading general surgical preparation we had already stated that 
for the electrophysiological experiments we have used 24 animals. In each animal we have only 
recorded the electrophysiological signal from one site. We have now specified this in the manuscript.  
 
Discussion: 
Page 21 line14: The authors state that their data "provide a plausible biology for a clinical effect of 
PAC1 blockade". I would tone down this statement. The demonstration of inhibition of stimulated 
activity in the trigemino-cervical complex in an experimental animal model that might be associated 
with the pathophysiology of primary headaches does not justify such a conclusion. 
We have now modified the sentence accordingly. 
 
The authors state that the antagonism at the PAC1 receptor may offer a new strategy for the 
preventive treatment of primary headache disorders. This "new strategy" is somehow contradicted by 
the fact that a clinical phase-2 trial with a monoclonal PAC1 receptor antibody has already been 
reported to be ineffective in the preventive treatment of migraine. Instead of presenting a "new 
strategy" this paper supports the hypotheses that, despite the current clinical evidence, antagonism 
of the PAC1 receptor might offer some therapeutically gain in primary headache disorders. 
Accordingly, the authors discuss that PAC1 antibodies might work rather in migraine patients with 
autonomic symptoms or in cluster headache. I would suggest restructuring this paragraph under this 
aspect. Additionally, please provide the citation of the abstract of the phase 2 AMG 301 study. 
We are aware of the fact that the phase 2 trial with AMG301 was negative. However, in our view it is 
much too early to conclude that the mechanism is ineffective in the preventive treatment of migraine. 
The main reason is that AMG 301 had a much lower affinity for the PAC1 receptor compared to Ab181. 
Given the amount of clinical and preclinical evidence supporting significant role of PACAP in the 
pathophysiology of migraine, it seems more likely that the lack of efficacy was based more on the 
specifications of AMG301 than on the mechanism itself. On top of this we have to consider the lack of 
distinction between migraine with and without autonomic symptoms and the complete lack of data on 
trigeminal autonomic cephalalgias. We will have more insight on the subject when the trials with 
monoclonal PACAP antibodies will have concluded and the results become available. Taken together, as 
we believe that AMG301 is not a good example to conclude that the mechanism is ineffective in 
migraine and as we have no data on trigeminoautonomic cephalalgias such as cluster headache, we 
have written that targeting the PAC1 receptor may offer a new strategy for the preventive treatment of 
primary headache disorders. Finally, we would like to cite the AMG301 data but they have only been 
presented as an e-poster at the EHF meeting 2019 and are not included in the abstract book published 
in the Journal of Headache and Pain. Hence, as much as we would like to, we can't cite the abstract. 
 
Minor points 
Introduction, line 44: The authors state that infusion of VIP "less reliably" induces migraine-like 
attacks. VIP does not induce migraine attacks as also demonstrated by the cited paper by Rahmann et 
al, Cephalalgia 2008 ("None of the subjects reported a migraine attack after VIP infusion."). Please 
correct. 
We are aware of the work of Rahmann et al. However, the data is not that clear since Amin et al (Brain 
2014; 137: 779-794) have shown that VIP may trigger attacks in some individuals. We therefore chose to 
use the terms "less reliably".  
 
Results: Fig 3.2. -> Please add in the results text the referral to the designated graph (A,B,C,D) 
We have now corrected this. 
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) may play an important role 
in primary headaches. Preclinical evidence suggests that PACAP38 modulates trigeminal 
nociceptive activity mainly through PAC1 receptors while clinical studies report that plasma 
concentrations of PACAP38 are elevated in spontaneous attacks of cluster headache and 
migraine and normalize after treatment with sumatriptan. Intravenous infusion of PACAP38 
induces migraine-like attacks in migraineurs and cluster-like attacks in cluster headache 
patients. 
A rodent-specific PAC1 receptor antibody Ab181 was developed and its effect on nociceptive 
neuronal activity in the trigeminocervical complex was investigated in vivo in an 
electrophysiological model relevant to primary headaches.  
Ab181 is potent and selective at the rat PAC1 receptor and provides near maximum target 
coverage at 10 mg/kg for more than 48 hours. Without affecting spontaneous neuronal 
activity, Ab181 effectively inhibits stimulus-evoked activity in the trigeminocervical complex. 
Immunohistochemical analysis revealed its binding in the trigeminal ganglion and 
sphenopalatine ganglion but not within the CNS suggesting a peripheral site of action.  
The pharmacological approach using a specific PAC1 receptor antibody could provide a novel 
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Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) may play an important role 
in primary headaches. Preclinical evidence suggests that PACAP38 modulates trigeminal 
nociceptive activity mainly through PAC1 receptors while clinical studies report that plasma 
concentrations of PACAP38 are elevated in spontaneous attacks of cluster headache and 
migraine and normalize after treatment with sumatriptan. Intravenous infusion of PACAP38 
induces migraine-like attacks in migraineurs and cluster-like attacks in cluster headache 
patients. 
A rodent-specific PAC1 receptor antibody Ab181 was developed and its effect on nociceptive 
neuronal activity in the trigeminocervical complex was investigated in vivo in an 
electrophysiological model relevant to primary headaches.  
Ab181 is potent and selective at the rat PAC1 receptor and provides near maximum target 
coverage at 10 mg/kg for more than 48 hours. Without affecting spontaneous neuronal 
activity, Ab181 effectively inhibits stimulus-evoked activity in the trigeminocervical complex. 
Immunohistochemical analysis revealed its binding in the trigeminal ganglion and 
sphenopalatine ganglion but not within the CNS suggesting a peripheral site of action.  
The pharmacological approach using a specific PAC1 receptor antibody could provide a novel 








































































Migraine and cluster headache are highly disabling disorders [53] involving activation of the 
trigeminovascular system, which includes the perivascular meningeal afferents and the 
trigeminal ganglion in the peripheral nervous system, and the trigeminocervical complex 
(TCC) as well as higher brain structures including the hypothalamus, thalamus and 
periaqueductal gray in the central nervous system [18,34].  
  
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) has received increasing 
attention in the context of migraine and cluster headache. PACAP38 is a 38-amino acid 
neuropeptide that is structurally and functionally related to vasoactive intestinal peptide 
(VIP) [27,40]. Both neuropeptides act on the same set of receptors, namely PAC1, VPAC1 and 
VPAC2 receptors, which belong to the G-protein-coupled receptors of the secretin family 
[27]. PACAP38 [44] and VIP [22] have vasodilatory properties and play a major role in 
parasympathetic communication [7,27,36]. In cluster headache both neuropeptides are 
released during a spontaneous attack [15,52]. In migraine, despite some shared biology, 
both molecules have important differences. During a spontaneous migraine attack PACAP38 
is released into the cranial circulation regardless of the presence of autonomic symptoms 
[51,55] while VIP is only released if cranial autonomic symptoms accompany the attack [17]. 
The infusion of PACAP38 [2,26,45], but less reliably VIP [43], induce migraine-like attacks in 
which can be effectively treated with sumatriptan. Sumatriptan normalizes elevated levels 
of PACAP38 during migraine [55]. These findings strikingly resemble the preclinical and 
clinical observations made with calcitonin gene-related peptide (CGRP) [14,16,17,37,57] 






































































has been proven to be a validated target in the treatment of both disorders 
[13,18,24,30,39,47].  
 
A large body of preclinical evidence has supported and begun to dissect the mechanisms 
behind these clinical observations. The fact that PACAP38 and VIP share similar affinities to 
the VPAC1 and VPAC2 receptors but that the PAC1 receptor has a 100- to 1000-fold higher 
affinity to PACAP38 [9] has led to the conclusion that the relevant action of PACAP38 is likely 
to be mediated mainly through the PAC1 receptor [55]. These findings are supported by in 
vivo studies that demonstrate the release of PACAP38 into the cranial circulation upon 
peripheral trigeminal activation [55,56] and the facilitation of nociceptive neuronal 
transmission in the TCC that is reversible by the administration of a PAC1 receptor 
antagonist [1].  
 
These observations suggest that targeting the PAC1 receptor may offer an effective and 
highly selective approach to reduce trigeminal activation and offer a novel target for the 
treatment of primary headaches. We therefore developed a potent and selective 
monoclonal mouse anti-rat PAC1 antibody (Ab181), fully characterized the pharmacologic 
and pharmacokinetic properties of the agent, and studied its effect on nociceptive neuronal 
activity within the TCC in an in vivo model that has been proven to be highly predictive for 
clinical efficacy in primary headaches [19-21,50]. Preliminary results have been presented at 
the 5th European Headache and Migraine Trust International Congress [32] and the 








































































The generation and in vitro characterization of Ab181, the pharmacodynamic and 
pharmacokinetic analyses as well as the immunohistochemistry were conducted between 
2009 and 2013 in the Amgen laboratories in Thousand Oaks, CA, USA. The 
electrophysiological studies were conducted between 2012 and 2013 in the laboratory of 
the Headache Group at the Department of Neurology, University of California, San 
Francisco, CA, USA.  
 
The generation of the Ab181 
Mice anti-rat PAC1-specific monoclonal antibodies were generated using a conventional 
immunization method. Five 4-6-week old hybrid 129xC57BL/6 mice (Charles River 
Laboratories, Hollister, CA, USA) received three rounds of immunizations with soluble rat 
PAC1, chemically conjugated to Padre Peptides (Pan DR Helper T-cell epitopes). Mice were 
immunized SQ/IP with up to 50 µg of antigen mixed or emulsified in either Freund’s 
complete adjuvant (Cat# 77140, Pierce, Thermo Fisher Scientific, Waltham, MA, USA), RIBI 
(Cat# S6322, Sigma-Aldrich, St. Louis, MO, USA) or Poly I: C/CpG. Soluble PAC1 receptor 
polypeptides containing the N-terminal extracellular domains (ECDs) of rat PAC1 (amino 
acids 1-135 of GenBank accession no. NM133511.1) were generated by transiently 
cotransfecting 293-6E cells. All mice were maintained according to the regulations of the 
Amgen Institutional Animal Care and Use Committees (IACUC) in Thousand Oaks, CA. 
Mice with the highest detected FACS titer to Rat PAC1 expressed on CHO AMID cells were 
selected for fusion. Four days prior to spleen harvest, mice selected for fusion were given a 
final IP boost of 50 µg soluble rat PAC1 in PBS (Cat# 14040, GIBCO, Thermo Fisher Scientific, 






































































nonsecreting murine myeloma cells, Sp2/0-Ag14 (American Type Culture Collection), at a 
ratio of 2.5:1 by electrofusion. Ab181 is identified through screening assays including 
binding competition, functional blocking, and receptor selectivity against the rat PAC1 
receptor. 
 
In vitro characterization of AAb181 
Potency and selectivity of AbA181 were analyzed in vitro cell-based functional assay. 
 
Cell culture 
In house developed stable rPAC1/CHO cells were grown in Ham’s F12 nutrient mixture (Cat# 
11765, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA); 10% fetal bovine serum (FBS) 
(Cat# 10099, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA); 1X Penicillin-
Streptomycin-Glutamine (Cat# 10378, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA); 
400 µg/mL G418 (Cat# 10131, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA); 250 
µg/ml Zeocin (Cat# R250-01, Invitrogen, Thermo Fisher Scientific Waltham, MA, USA). All 
cell flasks were maintained in incubators at 37°C with 5% CO2. U2OS (Cat# HTB-96TM, ATCC, 
Manassas, VA, USA) cells were grown in the medium of McCoy's 5A (Cat# 16600, GIBCO, 
Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FBS (Cat# 10099, GIBCO, 
Thermo Fisher Scientific, Waltham, MA, USA), 1x L-glutamine (Cat# 25030, GIBCO, Thermo 
Fisher Scientific, Waltham, MA, USA), 1X Penicillin-Streptomycin-Glutamine and 1 X MEM 
Non-Essential Amino Acids (Cat# 11140, GIBCO, Thermo Fisher Scientific, Waltham, MA, 
USA). All cell flasks were maintained in incubator at 37°C with 5% CO2.  
 






































































The rVPAC1 and rVPAC2 BacMam virus constructs were prepared in house. The titer of 
rVPAC1 BacMam virus is 7.01 X 108 IU/ml, and the titer of rVPAC1 BacMam virus is 5.75 X 108 
IU/ml. 
 
Preparation of BacMam virus transduced rVPAC1 and rVAPC2 cells: 
U2OS cells were cultured in T-75 flask until the cell density reach to 70 - 80% confluent 
before transduction. Cell medium was removed from flask and the cells were rinsed with 1 X 
PBS (Cat# 14040, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) once, then Versene 
(Cat# 15040, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) was added to detach the 
cells. 3 X 106 U2OS cells were resuspended with culture medium and mixed with rVPAC1 or 
rVPAC2 BacMam virus at a concentration of 50 multiplicity of infection (MOI)/cell. The cell 
mixture was further incubated overnight for assay. 
 
Cell-based functional assay 
The cAMP assay was performed by using LANCE cAMP ultra assay kit (Cat # TRF0263, 
PerkinElmer Inc., Waltham, MA, USA) to determine the activity of Ab181. Assay buffer 
contain Ham's F12 nutrient mixture (Cat# 11765, GIBCO, Thermo Fisher Scientific, Waltham, 
MA, USA), 0.1% bovine serum albumin (BSA) (Cat# CR84-100, PerkinElmer, Inc., Waltham, 
MA, USA), 1 mM IBMX (Cat# I5879, Sigma-Aldrich, St. Louis, MO, USA). Agonist dose 
response curve was first run to determine the appropriate concentration to be used in 
subsequent antagonism studies (data not shown) (Figure 1 and Table 1).  
The antagonist activity of Ab181 was carried out by using EC80 of PACAP38 (Cat# H-8430, 






































































Switzerland). PACAP6-38 (Cat# H-2734, Bachem, Bubendorf, Switzerland), a PAC1 receptor 
antagonist, was used as a positive control. Ab181 (0.5 pM – 1 M) was pre-incubated with 
the rPAC1-CHO cell suspension (2,000 cells/well) at room temperature for 30 min prior to 
the addition of agonists. PACAP38 or maxadilan was then added and incubated with the 
mixture for additional 15 min at room temperature. The reaction was stopped by adding 
detection mix of Eu-cAMP tracer and ULightTM-anti-cAMP (Cat# TRF0263, PerkinElmer Inc., 
Waltham, MA, USA) to all wells. After a 45-min incubation at room temperature, the assay 
plate was read on an EnVision instrument (Cat# 2105-0100, Perkin-Elmer Inc., Waltham, 
MA, USA). 
 Same assay method was used to determine the activity of Ab181 on rVPAC1 and rVPAC2 
receptors. The activity of VIP (Cat#: H-3775, Bachem, Bubendorf, Switzerland), a rVPAC1 and 
rVPAC2 receptor agonist, was first evaluated and the EC80 concentration of VIP was used in 
the assay to determine the activity of Ab181 on these receptors. 
 
All results were analyzed using GraphPad Prism software’s nonlinear regression curve fit 
(GraphPad Software, Inc., La Jolla, CA, USA) and data are presented as mean ± SD.  Data 
from the agonist dose-response curves were used to calculate the half maximal effective 
concentration (EC50) and the half maximal inhibitory concentration (IC50) values for agonist 
and antagonist studies, respectively. 
 
Pharmacokinetic and pharmacodynamic analysis 
Male naïve Sprague Dawley rats, 6-12 weeks from either Taconic Farms Inc. (Oxnard, CA, 
USA) or Harlan Laboratories (Indianapolis, IN, USA) at the average age of initiation of 






































































the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the 
Office of Laboratory Animal Welfare. Animals were group-housed in non-sterile, ventilated 
micro-isolator housing on corn cob bedding in Amgen’s Assessment and Accreditation of 
Laboratory Animal Committee (AAALAC)-accredited facility with controlled temperature (70 
± 5º F), relative humidity (50 ± 20%), and 12-h light/dark cycles (0600 to 1800). Animals had 
ad libitum access to pelleted feed (Harlan Teklad 2020X, Indianapolis, IN, USA) and water 
(on-site generated reverse osmosis) via automatic watering system.  
 
Test and control materials 
Ab181 was generated from Amgen and diluted to a series of concentrations in A5Su (10 mM 
sodium acetate, 9% sucrose, pH = 5.0). An isotype control was used as a dummy antibody in 
A5Su at a concentration of 5 mg/ml. Maxadilan (trifluoroacetate salt, Bachem, Bubendorf, 
Switzerland) was used and a dosing solution was freshly prepared daily by dissolving 
maxadilan in 1X DPBS (Dulbecco's phosphate buffered saline) (Sigma-Aldrich, St. Louis, MO, 
USA) at a final concentration of 0.5 µg/ml. 
 
Laser Doppler Imaging 
A laser Doppler imager (Moor Instruments, Ltd, Wilmington, DE, USA) was used to measure 
DBF on the shaved skin of the rat abdomen. 
Following anesthetic with propofol on the test day, the rat’s abdominal area was shaved and 
each animal was placed in a supine position on a temperature-controlled circulating warm-
water heating pad to help maintain a stable body temperature during the study. After a 10 
to 15-min stabilization period, a black rubber O-ring (0.925 cm inner diameter, O-Rings 






































































a visible blood vessel. After placement of an O-ring on the selected area, a baseline (BL) DBF 
measurement was taken.  After the BL scan, the maxadilan solution prepared fresh daily in 
20 µl vehicle (DPBS) was injected intradermally at the center of the O-ring. The post-
maxadilan DBF was measured either every 15 min over a 60-min period or at specified time 
points such as 15 and 30 min. The O-ring serves as an area of interest in which the DBF will 
be analyzed within the O-ring. Ab181 was prepared in A5Su at different concentrations 
depend on the dose range and given in a single bolus i.v. injection. In this report, MIIBF was 
measured and expressed as % change from the baseline [100 x (individual post-agonist flux-
individual baseline flux)/individual baseline flux] or as % inhibition [(Mean of % change from 
BL from vehicle-treated animals - individual % change from BL from drug treated animals)/ 
Mean % change from BL from vehicle-treated animals]. 
  
Dose-response study at 48 h post Ab181 treatment 
Ab181 was administered via penile vein or tail vein at various doses (0.1, 0.3, 1 and 10 
mg/kg).  Forty-eight h later, rats received an intradermal maxadilan injection (10 ng in 20 µl 
DPBS) followed by post-maxadilan DBF scans every 15 min over a 60-min period. Following 
the final DBF scan, three rats that had been pre-treated with 10 mg/kg of Ab181 were 
allowed to recover from the propofol anesthesia, returned to their home cages and 
underwent a second DBF measurement at 168 h post-drug administration. Serum PK 
samples were taken via tail vein immediately prior to the first maxadilan challenge at 48 and 
168 h post Ab181 treatment. The post MIIBF scan time point for the later studies was 
determined based on the post-maxadilan DBF response from 15 to 60 min.  
 






































































Ab181 was administered via the penile vein at various doses (0.1, 0.3, 1, 3 and 10 mg/kg). 
Three hours later, rats received an intradermal maxadilan injection (10 ng of maxadilan in 20 
µl DPBS) followed by a post-MIIBF scan 15 min later. Serum PK samples were taken via tail 
vein immediately after the DBF scan (i.e., 3.25 h post Ab181 treatment). The time point was 
chosen to confirm that the receptor occupancy of Ab181 had reached and stayed at the 
desired pharmacodynamic measures when performing the electrophysiological studies.  
 
Time-course study of Ab181 at a dose of 10 mg/kg 
Ab181 was dosed intravenously at 10 mg/kg via either rat tail vein or penile vein at various 
pre-treatment times (0.5, 3, 6.25 h) prior to maxadilan challenge. The full time-course study 
was comprised of several experiments, including the 48- and 168 h post-Ab181 treatment 
studies described above. 
 
Statistical analysis of laser Doppler flow experiments 
All DBF results were expressed as the mean ± SEM. A one-way ANOVA followed by 
Dunnett’s Multiple Comparison Test (MCT) was used to assess the statistical significance of 
Ab181 effects relative to either vehicle or the control antibody. A p<0.05 was used to 
determine significance between any two groups. ED50 values were calculated in GraphPad 
Prism following logarithmic transformation and nonlinear fit of data using a sigmoidal dose-
response model with variable slope and with the top constrained to the resulting mean 
percent change in the corresponding control group (vehicle or control antibody-treated 








































































All experiments were approved by the Institutional Animal Care and Use Committee (IACUC) 
of the University of California, San Francisco. Experiments were conducted in accordance 
with the United States Public Health Service's Policy on Humane Care and Use of Laboratory 
Animals, the ARRIVE guidelines and the guidelines of the Committee for Research and 
Ethical Issues of the International Association of the Study of Pain (IASP).  
 
General surgical preparation 
Twenty-four male Sprague-Dawley rats (Charles River Laboratories, Hollister, CA, USA) were 
used in the experiments. In each animal only one experiment was conducted and recordings 
were performed from one site. The animals were anesthetized by an induction with a single 
dose of pentobarbital (60 mg/kg i.p.; Nembutal, Lundbeck, Deerfield, IL, USA) followed by a 
continuous infusion of propofol (20-25 mg/kg/h i.v.; Propoflo, Abbott, Abbott Park, IL, USA) 
for maintenance throughout the entire experiment. For the administration of the anesthetic 
and drugs both femoral veins were cannulated. The left femoral artery was cannulated for 
the continuous monitoring of arterial blood pressure.  
 
Physiological monitoring 
Rats were placed on a self-regulating homeothermic blanket system with a rectal probe 
(Harvard Apparatus, Holliston, MA, USA) and core body temperature was maintained at 37 ± 
0.5 ˚C. Arterial blood pressure was monitored from the femoral artery using a transducer 
(DTX Plus DT-XX, Becton Dickinson, Sandy, UT, USA) connected to an amplifier (PM-1000, 
CWE, Ardmore, PA, USA). Following a tracheostomy, animals were mechanically ventilated 
(3-5 ml/min, 75-90 strokes/min; 7025, Ugo Basile, Comerio, VA, Italy) with oxygen-enriched 






































































and CO2 concentration were continuously displayed and fed into a data acquisition system 
(Power 1401, Cambridge Electronic Design-CED, Cambridge, UK) and saved on a hard disk.  
 
Recording preparation 
The rat's heads were fixed in a stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). A 
craniotomy was performed over the parietal cortex with a dental burr using constant 
irrigation to reduce heat production. With this procedure the middle meningeal artery 
(MMA) was exposed without lesioning the dura mater. For electrical stimulation a bipolar 
stimulating electrode (NE200, Rhodes Medical Instruments, Summerland, CA, USA) was 
placed above the MMA touching the dura mater at either side of the blood vessel. The 
electrode was connected to a stimulus isolation unit (SIU5A, Grass Instruments, Quincy, MA, 
USA). 
For the extracellular recording of neuronal activity in the trigeminocervical complex (TCC) a 
C1 partial hemilaminectomy was performed and the spinal dura mater was removed. A 
tungsten electrode with a nominal impedance of 1 MΩ (TM31A10, World Precision 
Instruments, Sarasota, FL, USA) was then introduced in the TCC near the dorsal root entry 
zone. For the localization of optimal site for the extracellular recording, the electrode was 
advanced or retracted in 5 μm steps with a piezoelectric motor-driven micromanipulator. 
Wide dynamic range (WDR) neurons with convergent input from the dura mater and the 
facial skin were identified by their responsiveness to electrical stimulation of the 
perivascular afferents surrounding the MMA as well as innocuous brush and noxious pinch 
of the skin innervated by the first branch of the trigeminal nerve.  
 






































































Electrical stimulation of the perivascular meningeal afferents was performed applying 
electrical square wave pulses (10-18 V, 0.1-0.2 ms, 0.5 Hz, 20 sweeps) (S88, Grass 
Instruments, Quincy, MA, USA).  
The stimulus-evoked neuronal signal as well as the neuronal background activity were 
acquired by the recording electrode placed in the TCC. The electrical signal was fed into a 
headstage amplifier (NL100AK, Neurolog, Digitimer Welwyn Garden City, Hertfordshire, UK) 
and passed to an AC preamplifier (NL104, Neurolog, Digitimer Welwyn Garden City, 
Hertfordshire, UK) set to a gain of 1000x. The signal was then passed through a band-pass 
filter (bandwidth 300 Hz to 10 kHz) (NL125/126, Neurolog, Digitimer Welwyn Garden City, 
Hertfordshire, UK) and a 60 Hz noise eliminator (Humbug, Quest Scientific, Vancouver, BC, 
Canada) before further amplification by an AC-DC amplifier (NL106, Neurolog, Digitimer 
Welwyn Garden City, Hertfordshire, UK). This signal was fed to a gated amplitude 
discriminator (NL201 Neurolog, Digitimer Welwyn Garden City, Hertfordshire, UK) and a 
data acquisition system (Power 1401, Cambridge Electronic Design-CED, Cambridge, UK). 
Data was collected, analyzed and stored using Spike 5.2 software (Cambridge Electronic 
Design-CED, Hertfordshire, UK). The output of the gated amplitude discriminator was also 
fed into an audio amplifier (NL120, Neurolog, Digitimer Welwyn Garden City, Hertfordshire, 
UK) and loudspeaker as well as an oscilloscope to assist spike discrimination from 
background activity. For the analysis of stimulus-evoked neuronal activity post-stimulus 
histograms were produced online. Background activity gated through the amplitude 
discriminator was collected into successive bins.  
 






































































After completing the surgical procedure, the animals had a resting period of 30 min. 
Following this period, baseline recordings were obtained. These were obtained by 
calculating the mean of 3 series of post-stimulus histograms, each consisting of 20 electrical 
stimuli.  
Following the assessment of the baseline values Ab181 (10 mg/kg) or its vehicle (A5Su) were 
administered intravenously over 1 min. Due to the pharmacological properties of the 
antibody the animals underwent a second resting period of 2.5 h to allow sufficient time for 
the antibody to bind its target. After this second resting sumatriptan (10 mg/kg) or vehicle 
were administered intravenously over 1 min followed by another resting period of 30 min. 
Post-stimulus histograms were then established 180, 185, 190, 195, 200, 205, 210 and 225 
min after the administration of the first pharmacological intervention (Ab181 or vehicle) 
(Figure 3.1). Based on the treatments described above, animals were divided in 3 treatment 
groups, group 1 receiving the Ab181 (intervention 1) and sumatriptan vehicle (intervention 
2), group 2 receiving vehicle (intervention 1) and sumatriptan (intervention 2) and group 3 
receiving vehicle at both interventions (Figure 3.1). 
 
Statistical analysis 
Statistical analysis was performed using SPSS 22.0 software (IBM Corporation, Armonk, NY, 
USA). Data are expressed as percentages of baseline values with standard errors of the 
mean (±SEM).  Effects within a treatment group were calculated using the analysis of 
variance (ANOVA) with repeated measures applying the Greenhouse-Geisser correction of 
the assumption of sphericity was violated. Bonferroni correction was applied for multiple 






































































individual data points with the baseline value within one treatment group the dependent t-
test was used.  
 
Immunohistochemistry 
Adult male Sprague Dawley rats (n = 3 per group) were injected intravenously with Ab181 or 
a monoclonal mouse isotype control antibody against an unrelated target or vehicle. After 
3.5 h, animals were terminally anesthesized by FatalPlus™ (Vortech Pharmaceuticals, 
Dearborn, MI, USA) and perfused with ice cold phosphate-buffered saline (PBS) at pH 7.4 
(Cat# 14040, GIBCO, Thermo Fisher Scientific, Waltham, MA, USA) followed by 4% 
paraformaldehyde (Cat# P6148, Sigma-Aldrich, St. Louis, MO, USA) in PBS (Cat# 14040, 
GIBCO, Thermo Fisher Scientific, Waltham, MA, USA). The SPG, TG and brains were 
dissected and cryoprotected with 30% sucrose in PBS. 12 µm sections were cut, washed in 
PBS and incubated in 3% normal goat serum (NGS) and 0.3% TritonX-100 in PBS for one hour 
at room temperature. Sections were then washed in PBS and incubated with 
AlexaFluor™488 goat anti-mouse IgG (Invitrogen, Thermo Fisher Scientific Waltham, MA, 
USA) for 1 h at room temperature. After final washes in PBS (Cat# 14040, GIBCO, Thermo 
Fisher Scientific, Waltham, MA, USA), sections were cover slipped with Vectashield 
mounting medium with DAPI (Cat# H-1200, Vector Labs, Burlingame, CA, USA). The 
following additional controls were conducted: A set of sections from Ab181-dosed rats was 
incubated with secondary antibodies against rabbit (AlexaFluor™488 goat anti-rabbit IgG, 
Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) as negative control. As positive 
control for PAC1 staining a set of vehicle sections was incubated with 10 µg/ml Ab181 in 
blocking solution at 4 °C for 48 h before further processing with AlexaFluor™488 goat anti-














































































































































In vitro potency of the PAC1 receptor antibody Ab181 
Ab181 is a full antagonist of the rat PAC1 receptor. It dose-dependently inhibited PAC1 
receptor agonist PACAP38 or maxadilan, a PAC1 selective receptor agonist, induced cAMP 
accumulation in CHO cells expressing rat PAC1 receptors with IC50 of 20 ± 3.3 nM (n = 3) and 
4.5 ± 0.1 nM (n = 2), respectively (Figure 1, Table 1). Ab181 is selective to the PAC1 receptor.  
IC50 at rat VPAC1 and rat VPAC2 receptors against the agonist VIP is greater than 100 nM, the 
highest concentration tested. 
 
 
Pharmacokinetic and pharmacodynamic effect of Ab181 
Dose-response study at 48 h post Ab181 treatment 
Pretreatment of Ab181 48 h prior to maxadilan challenge prevented the maxadilan-induced 
increase in dermal blood flow (MIIDBF). The change in dermal blood flow (DBF) over 60 min 
post-maxadilan is depicted in Figure 2.1A. There was a statistically significant difference (p < 
0.001) between the vehicle-treated group and each of three Ab181 dose groups (0.3, 1 and 
10 mg/kg) at 15 min post maxadilan injection with a calculated ED50 of 0.16 mg/kg (CI95% = 
0.10-0.26 mg/kg). Serum concentration of Ab181 is plotted on the Y-axis of Figure 2.1B.   
  
Dose-response study at 3.25 h post Ab181 treatment  
A shorter pretreatment of Ab181 at various doses was also evaluated. A fifteen minute post-
maxadilan measurement was used in this study. The change in MIIDBF after 3.25 h post-
Ab181 is depicted in Figure 2.2. There was a statistically significant inhibition of the MIIDBF 






































































calculated ED50 of 0.95 mg/kg (CI95% = 0.59-1.51 mg/kg). Serum concentration of Ab181 is 
plotted on the Y-axis of Figure 2.2. 
 
Time-course study of Ab181 at a dose of 10 mg/kg 
A fifteen minute post-maxadilan measurement was used in this study. Ab181 at 10 mg/kg 
produced a statistically significant inhibition of the MIIDBF starting (p < 0.05) from a 
pretreatment time of 0.75 h and lasting through the last measured 168 h time point (Figure 
2.3). The resulting mean serum concentration at 1, 3, 6, 48 and 168 h post drug treatment is 
plotted on the Y-axis in Figure 2.3. 
 
Electrophysiological recordings 
Ab181 inhibits stimulus-evoked responses in the TCC 
The intravenous administration of Ab181 (Figure 3.1) induced a long-lasting inhibition of 
stimulus-evoked nociceptive neuronal activity within the TCC (F1.48, 5.91 = 8.43, p = 0.022). 
Compared to the baseline value, the effect was significant at all investigated time points 
throughout the entire observational period. Maximum inhibition reached -43 ± 13% (t7 = 
3.41, p = 0.011) compared to baseline.  
 
Sumatriptan, which was administered as a positive control, significantly reduced stimulus-
evoked responses in the TCC (F2.21, 15.49=4.97, p = 0.019). Similar to the Ab181 group, the 
inhibiting effect of sumatriptan was significant at all investigated time points reaching a 
maximum inhibition of -42 ± 15% (t7 = 2.78, p = 0.027) compared to baseline without 






































































In contrast, the intravenous administration of the vehicle did not affect stimulus-evoked 
neuronal activity (F2.21, 15.48 = 2.45, p = 0.115; Figure 3.2A, B). 
 
Neuronal background activity in the TCC is not affected by Ab181 
In contrast to the observed effect on stimulus-evoked neuronal activity, intravenous 
administration of Ab181 does not attenuate unspecific neuronal background activity within 
the TCC (F1.32, 5.27 = 0.767, p = 0.456). The same lack of effect on background activity was 
observed in animals treated with sumatriptan (F2.33, 16.28 = 0.821, p = 0.474) and those 
treated with vehicle (F1.68, 11.78 = 0.99, p = 0.385; Figure 3.2C).  
 
Arterial blood pressure is unaffected by Ab181 
Intravenous administration of Ab181 does not affect arterial blood pressure (F1.69, 6.78 = 
0.656, p = 0.525). In contrast, sumatriptan induced a significant decrease in arterial blood 
pressure (F2.55, 17.84 = 5.82, p = 0.008) throughout the entire observational period, reaching a 
maximum reduction of -13 ± 3% (t7 = 4.89, p = 0.002) compared to baseline without 
recovering until the end of the experiment. In the vehicle control group arterial blood 
pressure was unaffected (F2.29, 16.02 = 0.93, p = 0.426; Figure 3.2D).  
 
Immunohistochemistry 
To investigate whether Ab181 or the control antibody distributed into tissues of interest 
after intravenous administration, we treated satellite rats from the electrophysiology study, 
but dissected and fixed tissues of interest at the 3.5 h time point after injection. Using 
fluorescently labeled secondary antibodies against the Fc-portion of the antibodies we were 






































































Ab181-dosed rats, but not in rats dosed with control antibody (Figure 4). In contrast, no 
labeling above background was detected in spinal trigeminal nucleus or superior salivary 
nucleus of the brainstem as well as in the hypothalamus and thalamus indicating that Ab181 
did not cross the blood-brain-barrier or the amount of antibodies that entered the CNS after 
intravenous injection was below the detection threshold of the immunohistochemical 








































































PACAP38, first described in 1989 [40], is one of the key neurotransmitters of the 
parasympathetic system. Soon after its discovery, preclinical evidence suggested effects 
beyond its parasympathetic role, in particular in specific pain pathways related to headache 
[56]. Neuroanatomical and functional data obtained since strongly suggests a prominent 
role in primary headaches including cluster headache and migraine. Our data may provide a 
plausible under-pinning biology for a potential clinical effect of PAC1 blockade in these 
disorders. 
 
First, PACAP receptors (PAC1, VPAC1 and VPAC2) are located in several key areas along the 
trigeminovascular system. Within the central part of the pain pathways processing 
trigeminal pain they have been identified in the thalamus [28], hypothalamus [28] and the 
TCC [35] while in the peripheral part, they are located in the TG [35] and the meningeal 
vasculature [5,6]. Beyond that, they are found in the SPG [8] highlighting the relevance of 
PACAP38 in the parasympathetic system, as well as its potential role in the functional 
interaction between the trigeminal and parasympathetic systems, namely the 
trigeminoautonomic reflex. 
 
Secondly, from a functional perspective, PACAP38 may play a role in cluster headache and 
migraine since its plasma concentration is elevated in spontaneous attacks [52,55] and 
normalizes after effective attack-abortion with sumatriptan [55]. In addition, PACAP38 
triggers migraine-like attacks in migraineurs [26,44], most likely through an activation of the 
PAC1 receptor [55]. In the context of migraine, the ability to trigger attacks clearly 






































































animal models. For example, electrical stimulation of the superior sagittal sinus of the cat 
induces the release of PACAP38 into the cranial circulation [55,56]. In line, the 
administration of PACAP38 facilitates nociceptive neuronal activity in the TCC [1]. These 
functional features of PACAP38 strikingly resemble the preclinical [50] and clinical 
observations [16,17] made with CGRP which predicted clinical efficacy of six small molecule 
CGRP receptor antagonists [10,29,31,38,42,54] and CGRP/CGRP-receptor antibodies 
[11,23,46,48] in the acute and preventive treatment of migraine as well as a CGRP antibody 
in the preventive treatment of episodic cluster headache [13].   
 
Thirdly, the parasympathetic and trigeminal sensory systems connect and interact with each 
other. From an anatomic perspective, CGRP-positive sensory fibers project from the TG to 
the SPG [8] and in vivo data demonstrates that PACAP38 induces the release of CGRP from 
the TCC [35]. Nevertheless, the detailed molecular mechanisms behind the attack-triggering 
capability of PACAP38 and in particular the clinical relevance of the above described 
mechanism remain to be fully elucidated. Interestingly, the administration of PACAP38, 
despite creating an activation of the trigeminovascular system with the clinical picture of a 
migraine-like attack, does not induce the release of CGRP in a human model of migraine 
[26]. These results suggest that the PACAP38-induced effects on trigeminal activation are 
likely to be the result of a direct effect on nociceptive trigeminal neurons rather than a 
CGRP-mediated mechanism although both mechanisms do not exclude each other. In the 
case of a direct activation of either of the PACAP receptors, PACAP38 stimulates the 
cAMP/PKA pathway thereby increasing neuronal excitability [49]. In addition, all PACAP 
receptors may be modulated in their expression profile under chronic pain conditions [58]. 






































































produce neuronal sensitization may even play a role in the chronification of migraine. Based 
on this large body of evidence, we set out to develop a specific antibody against the PAC1 
receptor as this receptor, as outlined above, is most likely the most relevant PACAP receptor 
in mediating the attack-triggering effect of PACAP38 and to test its effects on a model 
system that represents significant elements of cluster headache and migraine 
pathophysiology [4]. 
 
PACAP38 is a non-selective agonist at all the PACAP receptors, and VIP is only mildly 
selective to the VPAC1 and VPAC2 receptors [27]. Maxadilan, on the other hand, is the most 
selective agonist at the PAC1 receptor [41], which allowed us to measure pharmacodynamic 
activities specifically mediated through the PAC1 receptor. Although some years have passed 
since PACAP38 was discovered [40], selective antagonists to the individual receptors in the 
PACAP receptor family are still lacking. Several peptide antagonists have been reported with 
mild selectivity between different receptors [5,9,25] but their pharmacokinetic properties, 
especially their very short plasma half-life, hindered their utility in in vivo pharmacology 
studies. Therefore, Ab181 was developed. As demonstrated in the Results section, it is a 
potent and selective antagonist at the PAC1 receptor, with no activity at the VPAC receptors. 
It also potent and selective inhibitor of maxadilan-induced increases in dermal blood flow in 
a time- and dose-dependent manner. Through the in vitro and in vivo profiling, Ab181 
demonstrated full target coverage of the PAC1 receptor at 3.5 h after intravenous 
administration and maintained sustained plasma concentration throughout the study 
duration. It is therefore the first ideal tool for the studying of selective PAC1 pharmacology 







































































The new results of the study show that the intravenous administration of Ab181 inhibits 
stimulus-evoked nociceptive activity in the TCC. Unlike conventional small molecular agents 
whose molecule weight (MW) are normally < 500, the much larger sized antibodies (MW > 
145KD) generally have a slower tissue distribution rate. As a result, it requires a substantial 
equilibrium period between the administration of the antibody and the initiation of the 
experiment before the assessment of its influence on stimulus-evoked activity. Therefore, 
the experimental design resembles more of a short-term preventive scenario than an acute 
reversal of nociceptive trigeminal activation. The results show that the extent of neuronal 
inhibition was almost identical to that observed with sumatriptan, suggesting a robust 
effect. The fact that we did not observe an effect on non-specific background activity 
reflects the specificity of the effect on nociceptive neuronal transmission. 
  and, beyond that, may also suggest a purely (or mainly) peripheral site of action. 
 
The exact site of action of PAC1 remains speculative. Literature suggested that agonist 
PACAP38, with MW >4000, triggers migraine-like attacks without crossing the blood-brain-
barrier [12]. However, passage of PACAP27 and PACAP38 across the blood-brain barrier has 
been suggested [3]. Here, immunohistochemical analysis of Ab181 found a minimum 
presence in CNS which suggests that the site of the modulating action on nociceptive 
activity is likely to be located outside of the CNS. This would be in line with the results 
obtained from the electrophysiological experiments showing no effect on neuronal 
background activity as well as the immunohistochemical analysis in which Ab181 was 
detected in the relevant peripheral structures but not within the CNS. These findings 
suggest that Ab181 does not cross the blood-brain barrier in a significant concentration, a 






































































a small amount of antibody reaches the CNS but remains below the immunohistochemical 
detection limit, however, target coverage with such small amount is unlikely sufficient for a 
full antagonism effect. Therefore, the current study with a selective PAC1 antagonist 
antibody supports the hypothesis that peripheral PAC1 receptor inhibition can be sufficient 
to abort or prevent attacks of cluster headache and migraine.  
 
Recently, a randomized, placebo-controlled trial (Phase 2) with a monoclonal PAC1 receptor 
antibody (AMG 301) was reported in abstract form to be ineffective in the preventive 
treatment of migraine. In the context of our data some comments are relevant. First, in our 
experiments we used an antibody that was developed for rodents and differs significantly in 
its pharmacological properties, including its affinity to the PAC1 receptor, for which it is 
more potent than the one used in the human Phase 2 trial. from the antibody used in the 
human Phase 2 trial. Secondly, while the available evidence suggests that the PAC1 receptor 
plays a relevant role in trigeminal activation, the possibility that VPAC receptors are  
clinically significant is an open issue. The fact that VIP may trigger migraine attacks in subset 
of migraineurs may support this hypothesis [2]. Finally, in the clinical trial patients were not 
stratified by the presence or absence of cranial autonomic symptoms. Therefore, it may be 
hypothesized that the ability of PACAP38 to induce migraine attacks may require an action 
on PAC1 receptors on trigeminal and parasympathetic neurons thereby increasing the 
activation of the trigeminoautonomic reflex. If this would be the case one could speculate of 
a higher relevance of this potentially therapeutic mechanism in migraine with cranial 







































































Taken together, the findings of our studies suggest that the PAC1 antibody Ab181 can inhibit 
nociceptive neuronal traffic so that this pharmacological approach may offer a new strategy 
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Fig. 1: Antagonist activity of Ab181 at rat rPAC1 CHO cell (rPAC1-CHO) against PACAP38 or 
maxadilan 
The antagonist activity of Ab181 at the rat PAC1 receptor was carried out by measuring the 
potency of Ab181 in inhibiting EC80 of agonist PACAP38 or maxadilan stimulated cAMP 
production. PACAP6-38, a PAC1 receptor antagonist, was used as a positive control. 
Full antagonist activity of Ab181 against both PACAP38 (A) and maxadilan (B) induced cAMP 
accumulation was observed in rPAC1-CHO cells with IC50 of 20 ± 3.3 nM (n = 3) and 4.5 ± 0.1 
nM (n = 2) against respective agonist. 
 
Fig 2.1: Prophylactic effect of Ab181 on maxadilan-induced increase in DBF in rats 48 h 
post drug treatment  
Rats were given i.v. bolus injection of Ab181 (0.1, 0.3, 1 and 10 mg/kg, n = 6-7 rats/group). 
48 h later, after obtaining a post-drug baseline (BL), maxadilan at a dose of 10 ng (in 20 µl 
DPBS) was injected intradermally. The dermal blood flow (DBF) was measured by a laser 
Doppler imager. Graph A: The increase in DBF (change from BL) caused by maxadilan 
injection over 60 min was expressed as % change from BL [= 100 x (individual post-
maxadilan flux - individual BL flux)/individual BL flux]. Graph B: % change from BL (left-axis) 
versus resulting serum concentrations (right-axis) at 15 min post maxadilan; Solid triangle 
represents % change from BL at 48 h post drug treatment (left-axis, mean  SEM), open bar 
represents serum concentration at 48 h post drug treatment (right-axis, mean  SD).  
***p<0.001, ****p<0.0001 compared to vehicle-treated group by one-way ANOVA followed 







































































Fig 2.2: Effect of Ab181 on a maxadilan-induced increase in DBF in rats 3.25 h post 
treatment 
Rats were given i.v. bolus injection of Ab181 (0.1, 0.3, 1, 3 and 10 mg/kg, n = 7-8 
rats/group).  3 h later, after obtaining a post-drug baseline (BL), maxadilan at a dose of 10 ng 
(in 20 µl DPBS) was injected intradermally. The dermal blood flow was measured by a laser 
Doppler imager. Solid triangle represents % change from baseline (mean  SEM, left axis), 
open bar represents resulting serum concentration (mean  SD, right axis). Control: Dummy 
antibody + vehicle (n = 13 rats).  **p<0.01, ****p<0.0001 compared to control group by 
one-way ANOVA followed by Dunnett’s MCT.   
 
Fig 2.3: Time-course of effect of Ab181 (at 10 mg/kg) on a maxadilan-induced increase in 
DBF in rats 
Rats were given i.v. bolus injection of Ab181 at 10 mg/kg with pretreatment time at 0.5, 3, 
6.25, 48 and 168 h prior to maxadilan challenge (n = 3-8 rats/group).  After obtaining a 
post-drug baseline (BL), maxadilan at a dose of 10 ng (in 20 µl DPBS) was injected 
intradermally. The dermal blood flow was measured by a laser Doppler imager. Solid 
triangle represents % Inhibition (mean  SEM, left-axis), open bar represents resulting 
serum concentration (mean  SD, right-axis).   
 
Figure 3.1: Timeline of the electrophysiological in vivo experiments 
Following the surgical procedure and the recording of baseline activity either Ab181 (10 
mg/kg) or vehicle (A5Su) were injected intravenously. After a resting period of 2.5 h to allow 
the distribution of the antibody throughout the circulation and the relevant tissues, 






































































period of 30 min to allow sumatriptan to act, stimulus-evoked and spontaneous neuronal 
activity was recorded in the TCC.  
 
Figure 3.2: Effect of Ab181 on neuronal activity in the TCC 
Ab181 effectively inhibited stimulus-evoked neuronal activity in the TCC (A). The maximum 
inhibition was very similar to the one observed after the intravenous administration of 
sumatriptan (B). In contrast, an inhibiting effect on spontaneous background activity was 
not observed (C). Ab181 did not affect arterial blood pressure throughout the entire course 
of the experiment (D). 
 
Figure 4: Distribution of Ab181 in tissues after intravenous dosing 
Ex vivo detection of the IgG-portion of Ab181 or control antibody after i.v. dosing in dural 
vessels, trigeminal ganglion (TG) and sphenopalatine ganglion (SPG) as well as spinal 
trigeminal nucleus caudalis (TNC), superior salivatory nucleus (SSN) and thalamus. Staining 
of neuronal and glial structures is detected in dura, TG and SPG of Ab181-dosed rats, but not 
in TNC, SSN or thalamus. Only background staining is detected after intravenous dosing with 












































































Table 1: Antagonist Activities (IC50) of Ab181 
The antagonist activity of Ab181 at the rat PAC1 receptor (rPAC1) was carried out by 
measuring the potency of Ab181 in inhibiting EC80 of agonist PACAP38 or maxadilan 
stimulated cAMP production. PACAP6-38, a PAC1 receptor antagonist, was used as a positive 
control. 
Similar assay was used to determine the activity of Ab181 at rat VPAC1 (rVPAC1) and rat 
VPAC2 (rVPAC2) receptors against the EC80 of agonist VIP. 
 
 rPAC1 rVPAC1 rVPAC2 
 Agonist PACAP38 maxadilan VIP VIP 
Ab181 (IC50, nM) 20 ± 3.3 
(n = 3) 






PACAP6-38 (IC50, nM) 266 ± 77 
(n = 3) 
2.9 ± 1.5  
(n=2) 
430 ± 79 
(n=2) 
38 ± 4 (n=2) 
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The obligations of this indemnification will survive any 
termination or expiration of this Agreement. 
c. The Publisher represents and warrants that it has the right 
and power to enter into this Agreement and to perform its 
obligations contained in this Agreement, and that the person 
executing this Agreement on the Publisher’s behalf is 
authorized to do so. 
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d. The Publisher hereby indemnifies the Author and agrees 
to defend and hold the Author harmless from and against 
any and all liability, damage, loss, costs or expenses 
(including reasonable attorney’s fees and costs of settlement) 
incurred by the Author arising out of, or relating to any 
misrepresentation in, or breach or alleged breach of the 
Publisher’s representations or warranties in this Agreement.  
If the Publisher fails to promptly or diligently pursue any 
defense of the Author, the Author may assume such defense 
at the Publisher’s expense.  The obligations of this 
indemnification will survive any termination or expiration of 
this Agreement. 
e. EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, 
NEITHER PARTY MAKES ANY OTHER, AND HEREBY 
DISCLAIMS ALL OTHER, REPRESENTATIONS AND 
WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, 
STATUTORY OR OTHERWISE, INCLUDING, WITHOUT 
LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, 
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, 
OR THE ABSENCE OF LATENT OR OTHER DEFECTS, 
ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, 
WHETHER OR NOT DISCOVERABLE. 
f.  EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, 
IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER 
PARTY BASED UPON ANY LEGAL THEORY FOR ANY SPECIAL, 
INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR EXEMPLARY 
DAMAGES ARISING OUT OF THIS LICENSE OR THE USE OF 
THE WORK, EVEN IF A PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. 
3. Creative Commons License.  
Creative Commons Licenses are subject to items selected in 
item 1, 2 and 3 in the Schedule B.   
 
a. CCBY-NC-ND – NonCommercial-NonDerivitives Creative 
Commons License 
 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution-
NonCommercial-NoDerivs 4.0 Creative Commons License, as 
currently displayed at 
http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode 
(the “CC BY-NC-ND”).  The Author acknowledges and agrees 
that that Publisher is the exclusive “Licensor”, as defined in 
the CC BY-NC-ND, of the Work and that the Publisher may 
make the Work freely available to all users under the terms 
of the CC BY-NC-ND. 
b. CCBY – Creative Commons License 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution 4.0 
Creative Commons License, as currently displayed at 
http://creativecommons.org/licenses/by/4.0/legalcode (the 
“CC BY”).  The Author acknowledges and agrees that that 
Publisher is the exclusive “Licensor”, as defined in the CC BY, 
of the Work and that the Publisher may make the Work 
freely available to all users under the terms of the CC BY. 
c. CCBY-NC – NonCommercial Creative Commons License 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution-
NonCommercial 4.0 Creative Commons License, as currently 
displayed at http://creativecommons.org/licenses/by-
nc/4.0/legalcode (the “CC BY-NC”).  The Author 
acknowledges and agrees that that Publisher is the exclusive 
“Licensor”, as defined in the CC BY-NC, of the Work and that 
the Publisher may make the Work freely available to all users 
under the terms of the CC BY-NC. 
4. Royalties.  
The Author acknowledges and agrees that this Agreement 
entitles the Author to no royalties or fees.  To the maximum 
extent permitted by law, the Author waives any and all rights 
the Author may have to collect royalties or other fees in 
relation to the Work or in respect of any use of the Work by 




a. Assignment.  This Agreement may not be assigned or 
transferred, in whole or in part, by either party without the 
prior written consent of the other party.  Notwithstanding 
the above, the Publisher may assign this Agreement without 
the written consent of the Author (i) to an entity succeeding, 
whether by sale, merger or other corporate reorganization, 
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to substantially all of the Publisher’s assets and business 
activity, or (ii) to a corporation or organization that obtains 
the right to publish the Journal from the Publisher.  The 
Publisher may assign this Agreement to any of its affiliates.  
This Agreement will be binding upon and inure to the 
benefit of the parties hereto and their respective successors 
and permitted assigns. 
b. Counterparts.  This Agreement may be executed in two or 
more counterparts, each of which shall be deemed an 
original, but all of which together shall constitute one and 
the same document.  Facsimile or Portable Document 
Format (PDF) signatures will be deemed original signatures 
for purposes of this Agreement. 
c. Entire Agreement; Amendment.  This Agreement sets forth 
the entire agreement of the parties on the subject hereof 
and supersedes all previous or contemporaneous oral or 
written representations or agreements relating to the rights 
and duties provided herein, and may not be modified or 
amended except by written agreement of the parties. 
d. Force Majeure.  Neither party shall be liable for any 
default or delay on its part in performing any obligation 
under this Agreement if such default or delay is caused by 
natural disaster, accident, war, civil disorder, strike or any 
other cause beyond the reasonable control of such party.  In 
the event that either party is prevented by such an 
occurrence or circumstance for a period of more than ninety 
(90) days from fulfilling its obligations under this Agreement, 
the other party may terminate this Agreement upon thirty 
(30) days’ written notice. 
e. Governing Law.  This Agreement shall be governed in all 
respects according to the laws of the State of New York 
without giving effect to the principles of conflict of law 
thereof. 
f. Headings.  All headings are for reference purposes only 
and shall not affect the meaning or interpretation of any 
provision hereof. 
g. Severability.  If any provision of this Agreement is held to 
be illegal, invalid, or unenforceable under the present or 
future laws, then such provision shall be revised by a court 
of competent jurisdiction to be enforceable if permitted 
under applicable law, and otherwise shall be fully severable.  
In any event, this Agreement shall be construed and 
enforced as if such illegal, invalid, or unenforceable provision 
had never comprised a part of this Agreement, and the 
remaining provisions of this Agreement shall remain in full 
force and effect and shall not be affected by the illegal, 
invalid, or unenforceable provision or by its severance from 
this Agreement. 
h. Status of the Parties.  The parties are independent 
contractors.  Nothing in this Agreement is intended to or 
shall be construed to constitute or establish any agency, 
joint venture, partnership or fiduciary relationship between 
the parties, and neither party has the right or authority to 
bind the other party nor shall either party be responsible for 
the acts or omissions of the other. 
i. Waiver; Amendment.  The waiver by either party of or the 
failure by either party to claim a breach of any provision of 
this Agreement shall not be, or be held to be, a waiver of 
any subsequent breach or affect in any way the further 
effectiveness of any such provision.  No term or condition of 
this Agreement may be waived except by an agreement by 
the parties in writing. 
j. Waiver of Jury Trial.  EACH PARTY HEREBY WAIVES ITS 
RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY 
DISPUTE OR LEGAL PROCEEDING ARISING OUT OF THIS 
AGREEMENT OR THE SUBJECT MATTER HEREOF. 
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